top of page
The Professional Network for Healthcare Experts
Cipla licenses Qilu's Keytruda biosimilar for the US
The agreement gives Cipla exclusive US commercialisation rights to Qilu Pharmaceutical's pembrolizumab biosimilar candidate QL2107, referencing Keytruda.
nuaxia
Sep 42 min read
Biocytogen licenses fully human VHH antibody to Qilu Pharmaceutical for neuroscience development
Biocytogen has granted Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody from its RenNano platform for the development of neuroscience therapies.
nuaxia
Sep 32 min read
bottom of page